SecBot SecBot
8-K ·Filed Jun 9, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001628280-26-041883
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

No trading action warranted. This is a routine annual meeting and director compensation update with no earnings, guidance, or operational news. Monitor next quarterly earnings for commercial progress of ZORYVE and pipeline updates.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.23
T+0 close · Jun 9, 2026 · via day close
Latest settled
+1.85%
T+60 · $23.66
Vs SPY
−4.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $23.23entry
  2. T+1 · 5mo ago +5.85%α +4.15% · $24.59
  3. T+5 · 5mo ago +10.50%α +7.07% · $25.67
  4. T+20 · 4mo ago +23.89%α +20.27% · $28.78
  5. T+60 · 2mo ago +1.85%α −4.73% · $23.66
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three proposals were approved, including the election of three Class III directors, ratification of Ernst & Young as independent auditor, and non-binding advisory approval of executive compensation. Separately, the Board approved an amended and restated Non-Employee Director Compensation Program, effective June 5, 2026, which sets annual cash retainers (e.g., $50,000 base for non-employee directors) and equity awards (initial option up to $350,000 grant date fair value, annual awards of ~$350,000 split 65% options / 35% RSUs). This is a routine governance filing with no material financial impact.

Key Facts

  • All three proposals at the 2026 Annual Meeting were approved by stockholders.
  • Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
  • Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 approved (107,867,442 for, 15,748 against, 261,364 abstentions).
  • Non-binding advisory approval of named executive officer compensation passed (88,728,269 for, 3,723,408 against, 824,860 abstentions, 14,868,017 broker non-votes).
  • Board approved Amended and Restated Non-Employee Director Compensation Program effective June 5, 2026.
  • Annual cash retainer for non-employee directors: $50,000; additional $40,000 for Non-Executive Chair.
  • Annual equity award grant date fair value approximately $350,000 per director (65% options, 35% RSUs).
  • Initial option grant for new directors: up to $350,000 grant date fair value, vesting over three years.

Financial Impact

No material financial impact. Director compensation changes are routine and within standard ranges for a $2.7B market cap biotech.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-041883
Exhibit: exhibit101amendedandrestat.htm0001628280-26-041883
Document: 0001628280-26-041883-index-headers.html0001628280-26-041883
Document: 0001628280-26-041883-index.html0001628280-26-041883
Document: 0001628280-26-041883.txt0001628280-26-041883

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026